A POLYPILL INTERVENTION TO IMPROVE ADHERENCE FOR SECONDARY CARDIOVASCULAR DISEASE PREVENTION IN SPAIN: A COST-EFFECTIVENESS STUDY

被引：4
|
作者：
Arrabal, N. [1 ]
Kaskens, L. [1 ]
Garcia-Alonso, F. [1 ]
Gracia, A. [1 ]
机构：
[1] Ferrer Int, Barcelona, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.883
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV114
引用
收藏
页码：A393 / A393
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial
    Singh, Kavita
    Crossan, Catriona
    Laba, Tracey-Lea
    Roy, Ambuj
    Hayes, Alison
    Salam, Abdul
    Jan, Stephen
    Lord, Joanne
    Tandon, Nikhil
    Rodgers, Anthony
    Patel, Anushka
    Thom, Simon
    Prabhakaran, Dorairaj
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 262 : 71 - 78
  • [22] Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
    Troche, CJ
    Tacke, J
    Hinzpeter, B
    Danner, M
    Lauterbach, KW
    EUROPEAN HEART JOURNAL, 1998, 19 : C59 - C65
  • [23] The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective
    Zomer, Ella
    Liew, Danny
    Tonkin, Andrew
    Trauer, James M.
    Ademi, Zanfina
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 285 : 1 - 5
  • [24] COST-EFFECTIVENESS OF A POLYPILL FOR PATIENTS WITH OR AT HIGH RISK OF CARDIOVASCULAR DISEASE IN AN NHS SETTING
    Crossan, C. J.
    Dehbi, H.
    Thom, S.
    Poulter, N.
    Lord, J.
    VALUE IN HEALTH, 2017, 20 (09) : A620 - A620
  • [25] Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in Spain and Germany
    Taylor, D. C.
    Pandya, A.
    Thompson, D.
    Chu, P.
    Graff, J.
    LaRosa, J. C.
    Grundy, S. M.
    Wenger, N. K.
    Shepherd, J.
    Drummond, M. F.
    VALUE IN HEALTH, 2006, 9 (06) : A345 - A345
  • [26] Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in spain and germany
    Taylor, D. C. A.
    Pandya, A.
    Thompson, D.
    Chu, P.
    Graff, J.
    LaRosa, J. C.
    Grundy, S. M.
    Shepherd, I.
    Wenger, N. K.
    Drummond, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 125 - 125
  • [27] Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
    Lopez-Lopez, Jose P.
    Gonzalez, Ana Maria
    Lanza, Paola
    Lopez-Jaramillo, Patricio
    VASCULAR HEALTH AND RISK MANAGEMENT, 2023, 19 : 605 - 615
  • [28] Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
    Linda J Cobiac
    Anne Magnus
    Jan J Barendregt
    Rob Carter
    Theo Vos
    BMC Public Health, 12
  • [29] Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study
    Cobiac, Linda J.
    Magnus, Anne
    Barendregt, Jan J.
    Carter, Rob
    Vos, Theo
    BMC PUBLIC HEALTH, 2012, 12
  • [30] Polypill to fight cardiovascular disease - Cost effectiveness of statins for primary prevention of cardiovascular events is questionable
    Messori, A
    Santarlasci, B
    Trippoli, S
    Vaiani, M
    BRITISH MEDICAL JOURNAL, 2003, 327 (7418): : 808 - 809
12345